191 related articles for article (PubMed ID: 23091827)
61. {blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Drug Ther Bull; 2014 Jan; 52(1):6-9. PubMed ID: 24401533
[TBL] [Abstract][Full Text] [Related]
62. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.
Ali A; Bailey C; Abdelhafiz AH
Age Ageing; 2012 Sep; 41(5):681-4. PubMed ID: 22378612
[TBL] [Abstract][Full Text] [Related]
63. [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].
Shevelev VI; Kanorskiĭ SG
Kardiologiia; 2012; 52(7):56-60. PubMed ID: 22839715
[TBL] [Abstract][Full Text] [Related]
64. Anticoagulant loses its lustre.
Mullard A
Lancet; 2012 Jan; 379(9813):301. PubMed ID: 22292162
[No Abstract] [Full Text] [Related]
65. Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Bauer KA
Stroke; 2013 Jun; 44(6 Suppl 1):S38-40. PubMed ID: 23709725
[No Abstract] [Full Text] [Related]
66. Next generation anticoagulants may push warfarin to the wayside.
Kirsch B
Manag Care; 2011 Feb; 20(2):33-6. PubMed ID: 21428128
[No Abstract] [Full Text] [Related]
67. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Aguilar MI; Kuo RS; Freeman WD
Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
[TBL] [Abstract][Full Text] [Related]
68. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
69. Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin.
Eikelboom JW; Bosch J
Evid Based Med; 2015 Jun; 20(3):117. PubMed ID: 25870161
[No Abstract] [Full Text] [Related]
70. Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.
Sawaya FJ; Musallam KM; Arnaout S; Rabah A; Sawaya J
Int J Cardiol; 2012 Jan; 154(2):e27-8. PubMed ID: 21624685
[No Abstract] [Full Text] [Related]
71. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
[TBL] [Abstract][Full Text] [Related]
72. Diffuse alveolar hemorrhage associated with dabigatran.
Yokoi K; Isoda K; Kimura T; Adachi T
Intern Med; 2012; 51(18):2667-8. PubMed ID: 22989848
[No Abstract] [Full Text] [Related]
73. Should the newer oral anticoagulants be withheld from patients with valvular AF?
Dalen JE
Chest; 2013 Aug; 144(2):369-370. PubMed ID: 23918100
[No Abstract] [Full Text] [Related]
74. Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services.
Atay JK; Fanikos J; Barnes GD; Ehle M; Coatney J; Piazza G; Froehlich JB; Goldhaber SZ
Am J Cardiol; 2013 Aug; 112(3):387-9. PubMed ID: 23647794
[TBL] [Abstract][Full Text] [Related]
75. The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
Kowey PR; Naccarelli GV
Am J Med; 2012 Aug; 125(8):732. PubMed ID: 22608987
[No Abstract] [Full Text] [Related]
76. Dabigatran - neurosurgical anathema?
Thomas PA; Schaerf NB; Rosenfeld JV
Med J Aust; 2013 Aug; 199(4):238-40. PubMed ID: 23984772
[No Abstract] [Full Text] [Related]
77. Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
Eikelboom JW; Hart RG
Stroke; 2015 Jan; 46(1):5-6. PubMed ID: 25406147
[No Abstract] [Full Text] [Related]
78. Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Ezekowitz MD; Kent AP
Circulation; 2014 Oct; 130(17):1505-14. PubMed ID: 25332278
[No Abstract] [Full Text] [Related]
79. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Szapary L; Fehér G; Bosnyák E; Deli G; Csécsei P
Ideggyogy Sz; 2013 May; 66(5-6):165-74. PubMed ID: 23909016
[TBL] [Abstract][Full Text] [Related]
80. On the cost-effectiveness of dabigatran.
Soler-Martínez S
Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):512. PubMed ID: 24776063
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
